Minimally invasive liver resection—more evidence of oncologic advantage

Liver resection for colorectal cancer liver metastases (CRCLM) improves survival in patients with metachronous and synchronous metastases, and adjuvant systemic chemotherapy (AC) is often utilized (1,2). Furthermore, the timing of AC seems to be important, with studies reporting a survival benefit to initiation within 8 weeks of resection (3,4).